<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211417</url>
  </required_header>
  <id_info>
    <org_study_id>DS107G-02</org_study_id>
    <nct_id>NCT02211417</nct_id>
  </id_info>
  <brief_title>Oral DS107G in Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dignity Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dignity Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and efficacy of DS107G (2 g) to placebo in patients with
      moderate to severe atopic dermatitis.

      DS107G capsules (2 g) will be orally administered for 8 weeks, and will be compared against
      placebo.

      This study will enroll approximately 100 adult patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will come to the clinic on 6 occasions: at screening, baseline, week 2, week 4, week
      8 (end of treatment/early termination) and week 10 (follow-up). The primary efficacy variable
      will be the IGA. Secondary efficacy variables will include IGA (Investigator's Global
      Assessment), SCORAD (Scoring Atopic Dermatitis) visual analog scale (VAS)), EASI, BSA (Body
      Surface Area), POEM (Patient Orientated Eczema Measure), DLQI (Dermatology Life Quality
      Index), and SCORAD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA (Investigator's Global Assessment)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA (Investigator's Global Assessment)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI (Eczema Area and Severity Index)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POEM (Patient Orientated Eczema Measure)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI (Dermatology Life Quality Index)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD (Score Atopic Dermatitis)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (visual analog scale) pruritis score</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA (Body surface area) affected</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEAE Treatment emergent adverse events</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>TEWL (Trans epidermal water loss)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma total DGLA (dihomo-gamma-linolenic acid) concentrations</measure>
    <time_frame>0, 4 and 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma freeDGLA (dihomo-gamma-linolenic acid) concentrations</measure>
    <time_frame>0, 4 and 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma total fatty acid profile</measure>
    <time_frame>0, 4 and 8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>DS107G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS107G 2g capsules taken by mouth daily for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules 2g taken by mouth daily for 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS107G</intervention_name>
    <arm_group_label>DS107G</arm_group_label>
    <other_name>DGLA (Dihomo-gamma-linolenic acid) 500 mg gelatin capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Liquid paraffin capsule to mimic DS107G 500 mg gelatin capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 18 years and older.

          -  Moderate to severe atopic dermatitis.

        Exclusion Criteria:

          -  Clinically significant impairment of renal or hepatic function.

          -  History of hypersensitivity to any substance in DS107G or placebo capsules.

          -  Treatment with any experimental drug within 30 days prior to Day 0 visit (baseline).

          -  Excessive sun exposure, use of tanning booths or other ultraviolet (UV) light sources
             and/or is planning a trip to sunny climate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Climax, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Dignity Sciences Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Sciences investigational site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scollan ND, Choi NJ, Kurt E, Fisher AV, Enser M, Wood JD. Manipulating the fatty acid composition of muscle and adipose tissue in beef cattle. Br J Nutr. 2001 Jan;85(1):115-24.</citation>
    <PMID>11227040</PMID>
  </reference>
  <reference>
    <citation>Kawashima H, Toyoda-Ono Y, Suwa Y, Kiso Y. Subchronic (13-week) oral toxicity study of dihomo-gamma-linolenic acid (DGLA) oil in rats. Food Chem Toxicol. 2009 Jun;47(6):1280-6. doi: 10.1016/j.fct.2009.03.001. Epub 2009 Mar 9.</citation>
    <PMID>19275928</PMID>
  </reference>
  <reference>
    <citation>Makrides M, Simmer K, Neumann M, Gibson R. Changes in the polyunsaturated fatty acids of breast milk from mothers of full-term infants over 30 wk of lactation. Am J Clin Nutr. 1995 Jun;61(6):1231-3.</citation>
    <PMID>7762522</PMID>
  </reference>
  <reference>
    <citation>Teraoka N, Kawashima H, Shiraishi-Tateishi A, Tanaka T, Nakamura J, Kakutani S, Kiso Y. Oral supplementation with dihomo-gamma-linolenic acid-enriched oil altered serum fatty acids in healthy men. Biosci Biotechnol Biochem. 2009 Jun;73(6):1453-5. Epub 2009 Jun 7.</citation>
    <PMID>19502748</PMID>
  </reference>
  <reference>
    <citation>Tanaka T, Kakutani S, Horikawa C, Kawashima H, Kiso Y. Oral supplementation with dihomo-Î³-linolenic acid (DGLA)-enriched oil increases serum DGLA content in healthy adults. Lipids. 2012 Jun;47(6):643-6. doi: 10.1007/s11745-012-3664-3. Epub 2012 Mar 14.</citation>
    <PMID>22411689</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

